SHAREHOLDER ALERT: BMRN AMRN HMLP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines - Yahoo Finance
NEW YORK, NY / ACCESSWIRE / November 3, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=20841&wire=1
Lead Plaintiff Deadline: December 22, 2021
Class Period: January 13, 2020 - September 3, 2021
Allegations against BMRN include that: (i) BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase, was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the Food and Drug Administration would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Amarin Corporation Plc (NASDAQ:AMRN)
If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/amarin-corporation-plc-loss-submission-form?prid=20841&wire=1
Lead Plaintiff Deadline: December 23, 2021
Class Period: December 5, 2018 - June 21, 2021
Allegations against AMRN include that: (i) there was an increasingly high risk that certain of Amarin's patents would be invalidated; (ii) once the District Court invalidated certain of Amarin's patents, there was little to no chance of reversing that ruling; (iii) the Company's litigation was preventing it from effectuating a successful takeover; (iv) Defendants were downplaying the true threat the ongoing abbreviated new drug application litigation posed to the Company's business and future prospects; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
source: https://finance.yahoo.com/news/shareholder-alert-bmrn-amrn-hmlp-094000047.html
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.